Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial Redazione 19 Novembre 2020 ...
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation Redazione 12 Novembre 2020 ...
Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors Redazione 12 Novembre 2020 ...
Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors Redazione 12 Novembre 2020 ...
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study Redazione 5 Novembre 2020 ...
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis Redazione 5 Novembre 2020 ...
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program Redazione 5 Novembre 2020 ...